Shares of Alvotech, the Iceland-headquartered biosimilar developer, rocketed 14.4% to ISK 445 on July 30, extending a two-session rally of roughly 26% from last week's trough of ISK 389. The move comes without any new company-specific catalyst, raising a pointed question: is the market correcting an overshoot to the downside, or are traders chasing momentum in a name still clouded by fundamental uncertainty? This changes the picture significantly — there is a fundamental catalyst. Let me refine the analysis with this FDA inspection news.
Alvotech Clears a Key FDA Hurdle and Surges 14% — But Can a Copycat-Drug Maker Grow Into Its Ambitions?
Shares of Alvotech vaulted 14.4% to ISK 445 on July 30, extending a ferocious two-session rally after the biosimilar maker disclosed a critical regulatory win. The bounce reverses a punishing slide from ISK 437 to ISK 389 over the prior week, driven by lingering anxiety from a disappointing first quarter and broader biosimilar-sector jitters — and now forces investors to decide whether the stock's recovery has legs.
• An FDA Green Light Sparked the Reversal. On July 29, Alvotech announced that the FDA closed its inspection of the company's Reykjavik manufacturing facility, classifying the outcome as "Voluntary Action Indicated" (VAI) — a rating that means minor issues were found but no enforcement action is required. That matters because Alvotech's CEO said the company is "confident that the actions we have taken have effectively addressed the observations identified" and that it continues to work with the FDA to advance its drug applications toward approval . For shareholders, this removes a major overhang: FDA approvals remain "the biggest risk and source of potential earnings volatility."
• A Weak Quarter Still Haunts the Bull Case. In May, Alvotech reported Q1 revenue of $105.9 million, badly missing the $143.7 million consensus, while adjusted earnings per share swung to -$0.09 versus expectations of a small profit . Management blamed a production slowdown tied to facility upgrades, saying it "expects a recovery in product revenues as normal operations resume." Investors will test that promise when Q2 results arrive on August 19.
• Three New U.S. Drug Approvals Could Transform Revenue. Alvotech is guiding for $650–$700 million in 2026 revenue and aims to have five U.S. biosimilars on the market by year-end, up from two today, adding copycat versions of blockbuster drugs for arthritis, eye disease, and bone loss . The company has resubmitted applications for two of those products and won FDA acceptance of a third . Each approval unlocks a share of multi-billion-dollar branded-drug markets.
• The Gap Between Promise and Proof Remains Wide. High debt levels and uneven milestone-based revenues could still pressure the business , even as the pipeline broadens. Analysts project $1.4 billion in revenue by 2028, requiring roughly **37% annual growth — an aggressive clip for a company that just missed its quarter by a wide margin. The FDA clearance is necessary progress, not a finish line.